Barinthus Biotherapeutics (BRNS) on Friday reported "encouraging" results from its ongoing phase 2b HBV003 trial for chronic hepatitis B.
The study, involving 121 participants, assessed VTP-300 in combination with a low dose of anti-PD1 antibody nivolumab, and new data shows eight participants achieved complete HBsAg loss, while two met the criteria for a functional cure, the clinical-stage biopharmaceutical company said.
Barinthus said the ongoing study data shows that stronger responses could occur in patients treated with the VTP-300 and nivolumab. Preliminary safety data also showed that the treatment was well-tolerated, with no treatment-related serious adverse events reported as of the data cutoff, the company said.
Shares of Barinthus Biotherapeutics were down more than 16% in recent Friday trading.
Price: 1.12, Change: -0.26, Percent Change: -18.84
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.